Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin-induced cardiotoxicity

Cancer Gene Therapy volume 24, pages 203–207 (2017)Cite this article

Subjects

Abstract

Cancer treatments can have significant cardiovascular adverse effects that can cause cardiomyopathy and heart failure with reduced survival benefit and considerable decrease in the use of antineoplastic therapy. The purpose of this study is to assess the role of TLR2 and TLR4 gene expression as an early marker for the risk of doxorubicin-induced cardiomyopathy in correlation with early diastolic dysfunction in patients treated with doxorubicin. Our study included 25 consecutive patients who received treatment with doxorubicin for hematological malignancies (leukemia, lymphomas or multiple myeloma), aged 18–65 years, with a survival probability>6 months and with left ventricular ejection fraction>50%. Exclusion criteria consisted of the following: previous anthracycline therapy, previous radiotherapy, history of heart failure or chronic renal failure, atrial fibrillation, and pregnancy. In all patients, in fasting state, a blood sample was drawn for the assessment of TLR2 and TLR4 gene expression. Gene expression was assessed by quantitative reverse transcription PCR (qRT-PCR) using blood collection, RNA isolation, cDNA reverse transcription, qRT-PCR and quantification of the relative expression. At enrollment, all patients were evaluated clinically; an ECG and an echocardiography were performed. The average amount of gene expression units was 0.113 for TLR4 (range 0.059–0.753) and 0.218 for TLR2 (range 0.046–0.269). The mean mRNA extracted quantity was 113 571 ng/μl. As for the diastolic function parameters, criteria for diastolic dysfunction were present after 6 months in 16 patients (64%). In these patients, the mean values for TLR4 were 0.1198625 and for TLR2 were 0.16454 gene expression units. As for the diastolic function parameters, criteria for diastolic dysfunction were present after 6 months in 16 patients (64%). In these patients, the mean value for TLR2 was 0.30±0.19 and for TLR4 was 0.15±0.04. The corresponding values for the patients who did not develop diastolic dysfunction were 0.16±0.07 for TLR2 (P=0.01) and 0.11±0.10 for TLR4 (P=0.2). Our study suggests that TLR4 and TLR2 expression is higher in patients under doxorubicin therapy who develop diastolic dysfunction. This may suggest a predisposition to myocardial involvement, a higher sensitivity to doxorubicin cardiac effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Adamson P, Zile M, Cho Y, Bennett T, Bourge R, Aaron M et al. Hemodynamic factors associated with acute decompensated heart failure: part 2—use in automated detection. J Card Fail 2011; 17: 366–373.

    Article  Google Scholar 

  2. Bruynzeel A, Abou El Hassan M, Schalkwijk C, Berkhof J, Bast A, Niessen H et al. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 2007; 96: 937–943.

    Article  CAS  Google Scholar 

  3. Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, Petrini M et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005; 59: 541–544.

    Article  CAS  Google Scholar 

  4. Godaly G, Young D . Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation. Cell Microbiol 2005; 7: 591–601.

    Article  CAS  Google Scholar 

  5. Jurcut R, Wildiers H, Ganame J, D’hooge J, Paridaens R, Voigt J . Detection and monitoring of cardiotoxicity—what does modern cardiology offer? Support Care Cancer 2008; 16: 437–445.

    Article  Google Scholar 

  6. Komamura K . Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol Res Pract 2013; 2013: 1–6.

    Article  Google Scholar 

  7. Lim S . Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice. Int Immunopharmacol 2003; 3: 115–118.

    Article  CAS  Google Scholar 

  8. Malik M, Batchvarov V . Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36: 1749–1766.

    Article  CAS  Google Scholar 

  9. Nakamae H, Tsumura K, Akahori M, Terada Y, Yamane T, Hatashi T et al. QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment. Intern Med 2004; 43: 379–387.

    Article  CAS  Google Scholar 

  10. Neizel M, Korosoglou G, Lossnitzer D, Kühl H, Hoffmann R, Ocklenburg C et al. Impact of systolic and diastolic deformation indexes assessed by strain-encoded imaging to predict persistent severe myocardial dysfunction in patients after acute myocardial infarction at follow-up. J Am Coll Cardiol 2010; 56: 1056–1062.

    Article  Google Scholar 

  11. Park J, Marwick T . Use and limitations of E/e' to assess left ventricular filling pressure by echocardiography. J Cardiovasc Ultrasound 2011; 19: 169.

    Article  Google Scholar 

  12. Proença M . TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer. World J Gastroenterol 2015; 21: 7730.

    Article  Google Scholar 

  13. Puppe J, van Ooyen D, Neise J, Thangarajah F, Eichler C, Pfister R et al. Prospective evaluation of cardiac safety in breast cancer patients after adjuvant treatment with epirubicin, cyclophosphamide, doxetaxel and with or without trastuzumab: A single center experience. Geburtshilfe Frauenheilkd 2015; 12.

  14. Shi Y, Moon M, Dawood S, McManus B, Liu P . Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011; 36: 296–305.

    Article  CAS  Google Scholar 

  15. Soylu A, Ateş H, Cingöz S, Türkmen M, Demir B, Tunca M et al. TLR polymorphisms in FMF: association of TLR-2 (Arg753Gln) and TLR-4 (Asp299Gly, Thre399Ile) polymorphisms and myeloid cell TLR-2 and TLR-4 expression with the development of secondary amyloidosis in FMF. Inflammation 2010; 34: 379–387.

    Article  Google Scholar 

  16. Swain S, Whaley F, Ewer M . Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97: 2869–2879.

    Article  CAS  Google Scholar 

  17. Toll-like receptor-2 (TLR2); Toll-like receptor-4 (TLR4); interleukin-10 (IL-10). SciBX 2008; 1: 15.

  18. Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B . Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv 2011; 6: 95–101.

    Article  Google Scholar 

  19. Zile M, Adamson P, Cho Y, Bennett T, Bourge R, Aaron M et al. Hemodynamic factors associated with acute decompensated heart failure: part 1—insights into pathophysiology. J Card Fail 2011; 17: 282–291.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arad County Clinical Emergency Hospital, Arad, Romania,

    A L Pop-Moldovan, N -M Trofenciuc, D A Dărăbanţiu, C Precup & M Puşchiţă

  2. ‘Vasile Goldis’ Western University of Arad, Arad, Romania,

    A L Pop-Moldovan, N -M Trofenciuc, D A Dărăbanţiu, C Precup & M Puşchiţă

  3. ‘Victor Babeş’ University Of Medicine and Pharmacy, Timişoara, Romania

    H Branea & R Christodorescu

  4. Municipal Emergency Hospital, Timisoara, Romania

    H Branea & R Christodorescu

Authors
  1. A L Pop-Moldovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N -M Trofenciuc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D A Dărăbanţiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Precup
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Branea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Christodorescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Puşchiţă
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A L Pop-Moldovan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pop-Moldovan, A., Trofenciuc, NM., Dărăbanţiu, D. et al. Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin-induced cardiotoxicity. Cancer Gene Ther 24, 203–207 (2017). https://doi.org/10.1038/cgt.2017.4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2017.4

This article is cited by

Search

Advanced search

Quick links